Table 4 Likelihood of CA19-9 decline as a function of baseline CA19-9 value

From: Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer

  

Number of subjects with change in CA 19-9(%)

Baseline CA19-9 level

Range (U cc−3)

No decline

0–24% decline

25–49% decline

50–74% decline

75–100% decline

Total

Lowest quartile

75–972

5 (26.3%)

3 (15.8%)

4 (21.1%)

3 (15.8%)

4 (21.1%)

19

2nd quartile

973–3052

6 (31.6%)

1 (5.3%)

2 (10.5%)

4 (21.1%)

6 (31.6%)

19

3rd quartile

3053–12 815

4 (21.1%)

0 (0.0%)

2 (10.5%)

5 (26.3%)

8 (42.1%)

19

Highest quartile

>12 815

4 (21.1%)

1 (5.3%)

4 (21.1%)

4 (21.1%)

6 (31.6%)

19

Total

 

19

5

12

16

24

76

  1. CA19-9=carbohydrate antigen 19-9.
  2. The χ2 test shows that there is no significant association between baseline CA19-9 and likelihood or degree of marker decline (χ2=7.556, P=0.82).
Back to article page